| Overview |
| bs-13141R |
| FANCD2(Ser1404) Polyclonal Antibody |
| ELISA, FCM, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
| Human |
| Cow, Sheep, Pig, Horse, Rabbit |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human FANCD2 around the phosphorylation site of Ser1404 |
| Ser1404 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 2177 |
| Nucleus |
| FANCD2 phospho S1404; FANCD2 phospho Ser1404; p-FANCD2 phospho S1404; FA 4; FA D2; FA4; FAC D2; FACD 2; FACD; FACD2; FAD; FAD2; FANC D2; FANCD 2; FANCD; Protein FACD2; Type 4 Fanconi pancytopenia; FACD2_HUMAN; Fanconi anemia group D2 protein; Protein FACD2. |
| Fanconi Anemia (FANC) is a human autosomal-recessive cancer susceptibility disorder characterized by congenital defects, progressive bone marrow failure, and cellular hypersensitivity to mitomycin C (MMC). The FANC subunit D2 protein is vital for cellular resistance to DNA cross-linking and the arrest of DNA synthesis after ionizing radiation. DNA damage activates the monoubiquitination of FANC D2, targeting nuclear foci containing the BRCA 1 protein. |
| Application Dilution |
| ELISA |
1:500-1000 |
| FCM |
1:20-100 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| ICC |
1:100-500 |
Powered by Bioz